Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OQ1A
|
|||
| Drug Name |
JNJ-55308942
|
|||
| Indication | Anhedonia [ICD-11: MB24.2] | Phase 1 | [1] | |
| Mood disorder [ICD-11: 6A60-6E23] | Phase 1 | [2] | ||
| Neuroinflammation [ICD-11: 1D0Y] | Phase 1 | [1] | ||
| Company |
Johnson & Johnson
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2X purinoceptor 7 (P2RX7) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | The NLRP3 inflammasome | |||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.